COMP <GO>
LMAT vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
LeMaitre Vascular Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: LMAT 5
— MRK 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LMAT
LAST: $80.94 (-5.08%) • MKT CAP: $1.95B
balance-sheet
7.30
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMAT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMAT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.50% | 74.80% | -3.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | 20.70% | -6.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.3x | 15.3x | +13.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.17% | 3.42% | +0.75 | LMAT | /fcf-yield <GO> |
| Operating Margin | 27.20% | 34.30% | -7.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | 23.10% | 28.10% | -5.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 13.50% | 1.30% | +12.20 | LMAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.93% | 2.26% | -1.33 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 7.30 | 5.19 | +2.11 | LMAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.2 | 51.7 | +4.50 | LMAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.4x | 18.4x | +10.00 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $361.02B | -$359.07B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMAT REV | MRK REV | LMAT GROSS % | MRK GROSS % | LMAT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $249.6M | $65.01B | 71.5% | 74.8% | $81.3M | $12.36B |
| FY 2024 | $219.9M | $64.17B | 68.6% | 76.3% | $44.1M | $18.10B |
| FY 2023 | $193.5M | $60.12B | — | — | $36.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMAT // BETA —
MRK // BETA 0.92